PTCL with TFH phenotype
Conditions
Interventions
Experimental group:AC-CHOP regimen
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. De-novo PTCL with TFH phenotype, including AITL, FTH lymphoma and nodal PTCL with TFH phenotype, which are confirmed by pathology study; 2. Aged 18 to 75 years; 3. ECOG score <= 3; 4. Informed consent has been signed prior to carrying out any particular research operation; 5. Expected survival is at least 3 months, as determined by the investigator; 6. For men or women of reproductive age who have not undergone sterilization, consent to effective contraception during the treatment period and 12 months after the last study drug use is administered.
Exclusion criteria
Exclusion criteria: 1. Patients have receive and systemic or tropical chemotherapy except for corticosteroid prior to inclusion; 2. History or evidence of other malignant tumor; 3. Hisotry or evidence of CNS lymphoma infiltration; 4. Major surgical procedures were performed within 14 days of treatment of DLBCL; 5. Severe and uncontrolled cardiovascular disease; 6. Neutrophils 2 fold ULN); 8. Hepatic function abnormality (total bilirubin level > 2 fold ULN, transaminases> 3 fold ULN) unless these abnormalities are related to the lymphoma; 9. Uncontrolled and active systemic fungi, bacteria, viruses or other infections; 10. HIV infection; 11. Uncontrolled and active HBV and HCV infection; 12. Any situation that investigator found it inappropriate to join this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;Progression Free Survival;overall survival;Quality of Life; | — |
Countries
China
Contacts
Public ContactNiu Ting
West China Hospital, Sichuan University
Outcome results
None listed